Relmada Therapeutics Inc
Research Relmada Therapeutics Inc (RLMD) on Bullrun: market cap USD 374.41M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRLMD
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 374.41M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 12.91M
- Free cash flow-USD 9.61M
Valuation Snapshot
latest market cap is USD 374.41M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | USD 0 | -USD 45.79M | n/a | -1.45 | USD 3.50M | n/a | USD 86.51M |
| FY2024 | USD 0 | USD 0 | -USD 51.76M | n/a | -2.65 | USD 3.86M | n/a | USD 35.52M |
| FY2023 | USD 0 | USD 0 | -USD 51.66M | n/a | -3.28 | USD 4.09M | n/a | USD 85.36M |
| FY2022 | USD 0 | -USD 157.04M | -USD 103.80M | n/a | -5.3 | USD 5.40M | n/a | USD 140.44M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 374.41M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 354.20M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 15.69M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 124.61M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 105.05M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 624.98M | n/a | n/a | n/a |
About Relmada Therapeutics Inc
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Relmada Therapeutics Inc's market cap?
Relmada Therapeutics Inc's market capitalization is USD 374.41M.
What does Relmada Therapeutics Inc do?
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity.